Table 1 Baseline features of the patients in the KOBIO cohort at the start of TNFi treatment
Clinical feature | N = 776 |
|---|---|
Age, years, mean (SD) | 37.8 (12.5) |
Male gender, n (%) | 605 (78.0) |
Disease duration, years, mean (SD) | 8.1 (6.0) |
BMI, mean (SD) | 23.4 (3.5) |
Obesity, n (%) | 228 (29.4) |
Ever-smoker, n (%) | 385 (49.6) |
HLA-B27 positive, n (%)* | 696 (90.7) |
Ankylosing spondylitis, n (%) | 681 (87.8) |
TNFi naïve, n (%) | 608 (78.4) |
TNFi agent | |
Infliximab | 201 (25.9) |
Etanercept | 104 (13.4) |
Adalimumab | 282 (36.3) |
Golimumab | 189 (24.4) |
ESR, mm/h, mean (SD)† | 38.3 (30.5) |
CRP, mg/dL, mean (SD)‡ | 2.3 (2.8) |
PGA (0–10), mean (SD) | 6.2 (2.2) |
BASDAI (0–10), mean (SD) | 6.0 (1.9) |
ASDAS-CRP, mean (SD) | 3.6 (1.1) |
BASFI, mean (SD) | 3.5 (2.6) |